NMDP Amy Strelzer Manasevit Research Program
Supporting early-career physician-scientists focused on post-transplant complications
The NMDPSM Amy Strelzer Manasevit Research Program champions the careers of physician-researchers dedicated to addressing serious complications following hematopoietic cell transplant (HCT) and cell therapy. First awarded in 1998, the Amy Research Program is one of the largest and most coveted grants in HCT and cell therapy.
The Amy Research Program focuses on early career support to attract new talent to the field and encourage researchers to study ways to alleviate therapy-associated complications, such as infection, relapse or graft-versus-host disease. Amy Scholars receive a maximum of $400,000 divided over five years.
Application period open for the 2027 Amy Research Program
NMDP is now accepting proposals for the 2027 Amy Research Program. Proposals are due by 2 p.m. CDT on Thursday, Aug. 6, 2026. NMDP will announce the 2027 recipients at the 2027 Tandem Meetings held Feb. 17–20, 2027.
Grant application
Download the application for the 2027 NMDP Amy Strelzer Manasevit Research Program.
Application instructions
Access the Amy Research Program grant application instructions, including budget restrictions.
Proposal requirements
Review the Amy Research Program proposal requirements and applicant qualification criteria.
Key focus for 2027 proposals
For our 2027 awards, NMDP prefers proposals involving mismatched unrelated donor (MMUD) HCT. Such proposals could include the use of data and/or samples from NMDP-sponsored, CIBMTR®-led MMUD clinical trials as available. Questions? Email asmgrant@nmdp.org.
How the Amy Research Program impacts patients
The work of Amy Scholars leads to advances in HCT that make a difference in the lives of patients. Watch the video to learn how the program is driving forward research that addresses complications after transplant—and allows you to join the ranks of elite leaders in the field.
How the Amy Research Program benefited past scholars
The Amy award got me started in chronic graft-versus-host disease research, and that has been the focus of my career. We now have four new drugs approved to treat this complication. All of those approvals used evidence from the survey tool [I developed as part of the Amy Research Program] to support that we were benefiting patients."
Stephanie Lee, MD
Fred Hutchinson Cancer Research Center, 1998 Amy Scholar
Achieving funding through NMDP and the Amy Research Program is a significant milestone for young translational investigators working to improve the lives of patients after cell therapies. I aim to improve the lives of patients with AML."
Mark B. Leick, MD
Massachusetts General Hospital, 2025 Amy Scholar
Amy Research Program since 1998
55
$13 million+
$250 million+
Innovative research honors Amy Strelzer Manasevit
Amy was a young, vibrant mother of two who had a successful transplant after a multiple myeloma diagnosis in 1993. However, she succumbed to pneumonia and passed away just six weeks after returning home.
Her family and friends partnered with NMDP in 1997 to establish the research program. Their hope—prevent other families from losing loved ones because of complications from HCT.
NMDP relies on financial contributions from generous supporters to fund this critical research fellowship.
For more information about the Amy Research Program, email asmgrant@nmdp.org.
NMDP Barbara Buchbinder Nurse Research Program
In addition to supporting early-career physicians through the Amy Research Program, NMDP invests in pediatric HCT nurse researchers through the NMDP Barbara Buchbinder Nurse Research Program..